
Cetyl myristoleate (CMO) is the common name for cis-9-cetyl myristoleate. CMO was discovered in 1972 by Harry W. Diehl, Ph.D., a researcher at the National Institutes of Health. At the time, Dr. Diehl was responsible for testing anti-inflammatory drugs on lab animals. In order for him to test the drugs, he first had to artificially induce arthritis in the animals by injecting a heat-killed bacterium called Freund’s adjuvant. Dr. Diehl discovered that Swiss albino mice did not get arthritis after injection of Freund’s adjuvant. Eventually, he was able to determine that cetyl myristoleate was the factor present naturally in mice that was responsible for this protection. When CMO was injected into various strains of rats, it offered the same protection against arthritis.1
Cetyl myristoleate is found in certain animals, including cows, whales, beavers, and mice. As a nutritional supplement it is found in a highly purified, refined form in capsules and tablets. CMO is also available in creams and lotions for topical application.
CMO has been used in connection with the following conditions (refer to the individual health concern for complete information):
| Science Ratings | Health Concerns |
|---|---|
![]() |
|
Reliable
and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary studies
suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but minimal
or no scientific evidence. For a supplement, little scientific support and/or minimal health
benefit. |
|
Generally, CMO is taken in the amount of 400 to 500 mg daily for 30 days.
No side effects or drug interactions have been reported.
At the time of writing, there were no well-known drug interactions with cetyl myristoleate.
1. Diehl HW, May EL. Cetyl myristoleate isolated from Swiss albino mice: an apparent protective agent against adjuvant arthritis in rats. J Pharm Sci 1994;83:296-9.